Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Seegene, a biotechnology company, and Randox Laboratories, an international diagnostics company, have entered into an agreement in which Randox will obtain a non-exclusive license to Seegene's dual priming oligo technology to develop high-throughput diagnostic screening panels capable of simultaneously detecting a wide variety of infectious pathogens that cause either respiratory or sexually transmitted diseases.
Subscribe to our email newsletter
This agreement brings together two innovative technologies: Seegene’s dual priming oligo (DPO) multiplex polymerase chain reaction technology and Randox’s biochip array technology.
This combination facilitates highly sensitive and specific simultaneous detection of a broad range of pathogens from a single patient sample. This in turn will provide a more comprehensive and rapid clinical diagnosis of the patient, improving laboratory efficiency and ensuring timely delivery of appropriate treatments, the two companies said.
Jong-Yoon Chun, CEO of Seegene, and Peter FitzGerald, managing director of Randox, said: “Through this agreement, Randox will be able to complement the sensitivity and specificity of Biochip Arrays with Seegene’s multiplex DPO technology.
“As a result, the tests that are developed will provide clinical laboratories with a diagnostic system capable of detecting more infections with unparalleled accuracy and speed. We are excited that the products we are developing will be vital tools in the fight against the spread of debilitating infectious diseases.”